---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-001465"
form_type: "8-K"
ticker: "HRMY"
cik: "0001802665"
company_name: "Harmony Biosciences Holdings, Inc."
filed_at: "2024-02-22T23:59:59+00:00"
generated_at: "2026-06-05T19:57:14.138449+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Harmony Biosciences Q4 2023 revenue $168.4M, guides 2024 revenue $700-720M

## Summary
- WAKIX net revenue $168.4M in Q4 2023 (+31% YoY); full year $582.0M (+33%).
- GAAP diluted EPS $0.45 vs $0.79 YoY; non-GAAP adjusted EPS $0.73 vs $1.01.
- FDA granted priority review for WAKIX in pediatric narcolepsy; PDUFA June 21, 2024.
- 2024 net product revenue guidance $700-720M, up from ~$582M in 2023.
- Repurchased 3.2M shares for $100M in 2023; $150M remaining authorization.

## SEC filing metadata
- accession: 0001558370-24-001465
- form_type: 8-K
- ticker: HRMY
- cik: 0001802665
- company_name: Harmony Biosciences Holdings, Inc.
- filed_at: 2024-02-22T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802665/000155837024001465/0001558370-24-001465-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802665/000155837024001465/hrmy-20240222x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-001465
- JSON: https://secwatch.observer/filing/0001558370-24-001465.json
- Plain text: https://secwatch.observer/filing/0001558370-24-001465.txt

## Key facts
- Earnings Releases
  Harmony Biosciences Holdings, Inc. reported financial results for the quarter and year ended December 31, 2023.
  - Period: the quarter and year ended December 31, 2023
  - Result: reported results
  source text: On February 22, 2024, Harmony Biosciences Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1802665/000155837024001465/0001558370-24-001465-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.